General
Preferred name
NELFINAVIR
Synonyms
AG 1343 Mesylate ()
Viracept ()
AG1343 ()
Nelfin ()
NELFINAVIR MESYLATE ()
AG1341 ()
Nelfinavir (AG 1343) Mesylate ()
Viracept, AG1343 ()
Nelfinavir (Mesylate) ()
Nelfinavir-d3 ()
AG-1343 ()
Nelfinaviri mesilas ()
Nelfinavir methanesulfonate ()
Nelfinavir mesilate ()
NSC-747167 ()
P&D ID
PD008635
CAS
159989-65-8
159989-64-7
1217629-70-3
Tags
natural product
drug
available
Approved by
FDA
First approval
1997
Drug Status
withdrawn
approved
Max Phase
4.0
Drug indication
Antiviral
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCPRITION A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
DESCRIPTION Nelfinavir is an oral antiretroviral drug. It inhibits human immunodeficiency virus (HIV) protease. (GtoPdb)
DESCRIPTION Potent VEGFR, PDGFRbeta and KIT inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION An HIV-1 protease inhibitor. It inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. (BOC Sciences Bioactive Compounds)
Cell lines
2
Organisms
10
Compound Sets
25
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
Guide to Pharmacology
LINCS compound set
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Withdrawn 2.0
External IDs
71
Properties
(calculated by RDKit )
Molecular Weight
567.31
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
4
Rotatable Bonds
9
Ring Count
4
Aromatic Ring Count
2
cLogP
4.75
TPSA
101.9
Fraction CSP3
0.56
Chiral centers
5.0
Largest ring
6.0
QED
0.33
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Proteases/Proteasome
Anti-infection
Metabolic Enzyme/Protease
Target
HIV Protease
CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A7
HIV protease inhibitor
HIV
COVID-19,HIV Protease
Primary Target
Other Proteases
MOA
Inhibitor
HIV Protease inhibitor
Indication
human immunodeficiency virus (HIV-1)
ATC
J05AE04
VGSC Target
Nav1.5
Solubility
In Vitro:<br/>DMSO: ≥ 25 mg/mL (44.03 mM)
Source data